Prediction of <i>BRCA1</i> Status in Patients with Breast Cancer Using Estrogen Receptor and Basal Phenotype

Abstract

The use of cytokeratin staining in combination with ER and morphology provides a more accurate predictor of BRCA1 mutation status than previously available, that may be useful in selecting patients for BRCA1 mutation testing. The high percentage of BRCA1 cases positive for EGFR suggests that specific anti-tyrosine kinase therapy may be of potential benefit in these patients.